Shanghai Obio Technology (Group) Corp., Ltd. (SHA:688238)

SHA:688238 Revenue

Shanghai Obio Technology (Group) Corp. had revenue of 84.73M CNY in the quarter ending September 30, 2026, with 40.04% growth. This brings the company's total for the last twelve months to 293.86M, up 20.12% year-over-year. In the year 2025, Shanghai Obio Technology (Group) Corp. had annual revenue of 267.70M with 7.88% growth. That makes Shanghai Obio Technology (Group) Corp. the 28,867th largest company in the world by revenue and 4,886th in China.

• Revenue (ttm): 293.86M
• Revenue Growth: +20.12%
• P/S Ratio: 14.39
• Revenue / Employee: 406.44K
• Employees: 723
• Market Cap: 4.24B

Revenue Chart

Chart

Chart

Revenue by Segment

By Segment

Chart

• Gene Therapy CDMO Service 135.64M 50.7%
• Gene Therapy CRO Service 93.23M 34.9%
• Biological Agents, Reagents and Others 34.70M 13.0%
• Regenerative Medicine Services 3.85M 1.4%

By Geography

Chart

• Eastern Region 130.72M 48.9%
• North China 65.44M 24.5%
• South China 32.19M 12.0%
• Other 14.30M 5.3%
• Southwest District 11.40M 4.3%
• Central China 10.67M 4.0%
• Overseas 2.69M 1.0%

Fiscal year ended Dec 31, 2025 See the full SHA:688238 breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	267.70M	19.55M	7.88%
Dec 31, 2024	248.15M	43.34M	21.16%
Dec 31, 2023	204.81M	-86.50M	-29.69%
Dec 31, 2022	291.30M	36.36M	14.26%
Dec 31, 2021	254.95M	112.18M	78.57%

Data Source: S&P Global Market Intelligence Last updated: Oct 28, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Nov 4, 2026

Data Sources Report a data error